ID   CBL_HUMAN               Reviewed;         906 AA.
AC   P22681; A3KMP8;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   07-JUL-2009, sequence version 2.
DT   10-MAY-2017, entry version 208.
DE   RecName: Full=E3 ubiquitin-protein ligase CBL;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:10514377, ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:17509076};
DE   AltName: Full=Casitas B-lineage lymphoma proto-oncogene;
DE   AltName: Full=Proto-oncogene c-Cbl;
DE   AltName: Full=RING finger protein 55;
DE   AltName: Full=RING-type E3 ubiquitin transferase CBL {ECO:0000305};
DE   AltName: Full=Signal transduction protein CBL;
GN   Name=CBL; Synonyms=CBL2, RNF55;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2030914;
RA   Blake T.J., Shapiro M., Morse H.C. III, Langdon W.Y.;
RT   "The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl
RT   was generated by a large truncation encompassing a proline-rich domain
RT   and a leucine zipper-like motif.";
RL   Oncogene 6:653-657(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION BY HCK, AND INTERACTION WITH HCK.
RX   PubMed=10092522; DOI=10.1006/bbrc.1999.0427;
RA   Howlett C.J., Bisson S.A., Resek M.E., Tigley A.W., Robbins S.M.;
RT   "The proto-oncogene p120(Cbl) is a downstream substrate of the Hck
RT   protein-tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 257:129-138(1999).
RN   [5]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=10514377; DOI=10.1126/science.286.5438.309;
RA   Joazeiro C.A., Wing S.S., Huang H.-K., Leverson J.D., Hunter T.,
RA   Liu Y.-C.;
RT   "The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-
RT   dependent ubiquitin-protein ligase.";
RL   Science 286:309-312(1999).
RN   [6]
RP   INTERACTION WITH BLK.
RX   PubMed=8083187;
RA   Donovan J.A., Wange R.L., Langdon W.Y., Samelson L.E.;
RT   "The protein product of the c-cbl protooncogene is the 120-kDa
RT   tyrosine-phosphorylated protein in Jurkat cells activated via the T
RT   cell antigen receptor.";
RL   J. Biol. Chem. 269:22921-22924(1994).
RN   [7]
RP   PHOSPHORYLATION BY EGFR, AND INTERACTION WITH EGFR.
RX   PubMed=7657591; DOI=10.1074/jbc.270.35.20242;
RA   Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.;
RT   "Tyrosine phosphorylation of the c-cbl proto-oncogene protein product
RT   and association with epidermal growth factor (EGF) receptor upon EGF
RT   stimulation.";
RL   J. Biol. Chem. 270:20242-20245(1995).
RN   [8]
RP   INTERACTION WITH ZAP70.
RX   PubMed=9407100; DOI=10.1074/jbc.272.52.33140;
RA   Lupher M.L. Jr., Songyang Z., Shoelson S.E., Cantley L.C., Band H.;
RT   "The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and
RT   binds to the Tyr292 negative regulatory phosphorylation site of ZAP-
RT   70.";
RL   J. Biol. Chem. 272:33140-33144(1997).
RN   [9]
RP   PHOSPHORYLATION BY SYK AND FYN.
RX   PubMed=9535867; DOI=10.1074/jbc.273.15.8867;
RA   Deckert M., Elly C., Altman A., Liu Y.C.;
RT   "Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn
RT   and Syk tyrosine kinases.";
RL   J. Biol. Chem. 273:8867-8874(1998).
RN   [10]
RP   INTERACTION WITH LAT2.
RX   PubMed=12486104; DOI=10.1084/jem.20021405;
RA   Brdicka T., Imrich M., Angelisova P., Brdickova N., Horvath O.,
RA   Spicka J., Hilgert I., Luskova P., Draber P., Novak P., Engels N.,
RA   Wienands J., Simeoni L., Oesterreicher J., Aguado E., Malissen M.,
RA   Schraven B., Horejsi V.;
RT   "Non-T cell activation linker (NTAL): a transmembrane adaptor protein
RT   involved in immunoreceptor signaling.";
RL   J. Exp. Med. 196:1617-1626(2002).
RN   [11]
RP   INTERACTION WITH CSF1R, AND PHOSPHORYLATION.
RX   PubMed=11850825; DOI=10.1038/sj.onc.1205166;
RA   Wilhelmsen K., Burkhalter S., van der Geer P.;
RT   "C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel
RT   phosphorylation site in the receptor's carboxy-terminus.";
RL   Oncogene 21:1079-1089(2002).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION, MUTAGENESIS OF
RP   CYS-381, AND INTERACTION WITH HCK.
RX   PubMed=11896602; DOI=10.1038/sj.onc.1205228;
RA   Howlett C.J., Robbins S.M.;
RT   "Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated
RT   cellular transformation.";
RL   Oncogene 21:1707-1716(2002).
RN   [13]
RP   INTERACTION WITH FGR, AND PHOSPHORYLATION BY FGR.
RX   PubMed=12435267; DOI=10.1042/BJ20021201;
RA   Melander F., Andersson T., Dib K.;
RT   "Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-
RT   induced c-Cbl-mediated ubiquitination in adherent human neutrophils.";
RL   Biochem. J. 370:687-694(2003).
RN   [14]
RP   INTERACTION WITH SH2B2.
RX   PubMed=10374881; DOI=10.1038/sj/leu/2401397;
RA   Wakioka T., Sasaki A., Mitsui K., Yokouchi M., Inoue A., Komiya S.,
RA   Yoshimura A.;
RT   "APS, an adaptor protein containing pleckstrin homology (PH) and Src
RT   homology-2 (SH2) domains inhibits the JAK-STAT pathway in
RT   collaboration with c-Cbl.";
RL   Leukemia 13:760-767(1999).
RN   [15]
RP   INTERACTION WITH SH2B2.
RX   PubMed=9989826; DOI=10.1038/sj.onc.1202326;
RA   Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S.,
RA   Sasaki A., Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.;
RT   "APS, an adaptor protein containing PH and SH2 domains, is associated
RT   with the PDGF receptor and c-Cbl and inhibits PDGF-induced
RT   mitogenesis.";
RL   Oncogene 18:759-767(1999).
RN   [16]
RP   INTERACTION WITH SLA AND ZAP70, AND MUTAGENESIS OF GLY-306.
RX   PubMed=10449770; DOI=10.1073/pnas.96.17.9775;
RA   Tang J., Sawasdikosol S., Chang J.-H., Burakoff S.J.;
RT   "SLAP, a dimeric adapter protein, plays a functional role in T cell
RT   receptor signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:9775-9780(1999).
RN   [17]
RP   INTERACTION WITH SLA2.
RX   PubMed=11696592; DOI=10.1084/jem.194.9.1263;
RA   Holland S.J., Liao X.C., Mendenhall M.K., Zhou X., Pardo J., Chu P.,
RA   Spencer C., Fu A.C., Sheng N., Yu P., Pali E., Nagin A., Shen M.,
RA   Yu S., Chan E., Wu X., Li C., Woisetschlager M., Aversa G.,
RA   Kolbinger F., Bennett M.K., Molineaux S., Luo Y., Payan D.G.,
RA   Mancebo H.S.Y., Wu J.;
RT   "Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel
RT   inhibitor of antigen receptor signaling.";
RL   J. Exp. Med. 194:1263-1276(2001).
RN   [18]
RP   INTERACTION WITH CD2AP.
RX   PubMed=11067845; DOI=10.1074/jbc.M005784200;
RA   Kirsch K.H., Georgescu M.M., Shishido T., Langdon W.Y., Birge R.B.,
RA   Hanafusa H.;
RT   "The adapter type protein CMS/CD2AP binds to the proto-oncogenic
RT   protein c-Cbl through a tyrosine phosphorylation-regulated Src
RT   homology 3 domain interaction.";
RL   J. Biol. Chem. 276:4957-4963(2001).
RN   [19]
RP   INTERACTION WITH SH2B2, MUTAGENESIS OF TYR-371; TYR-700; TYR-731 AND
RP   TYR-774, AND PHOSPHORYLATION AT TYR-371; TYR-700 AND TYR-774.
RX   PubMed=11997497; DOI=10.1128/MCB.22.11.3599-3609.2002;
RA   Liu J., Kimura A., Baumann C.A., Saltiel A.R.;
RT   "APS facilitates c-Cbl tyrosine phosphorylation and GLUT4
RT   translocation in response to insulin in 3T3-L1 adipocytes.";
RL   Mol. Cell. Biol. 22:3599-3609(2002).
RN   [20]
RP   INTERACTION WITH INPPL1.
RX   PubMed=12504111; DOI=10.1016/S0006-291X(02)02894-2;
RA   Vandenbroere I., Paternotte N., Dumont J.E., Erneux C., Pirson I.;
RT   "The c-Cbl-associated protein and c-Cbl are two new partners of the
RT   SH2-containing inositol polyphosphate 5-phosphatase SHIP2.";
RL   Biochem. Biophys. Res. Commun. 300:494-500(2003).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T.,
RA   Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using
RT   mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [23]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-
RT   dependent protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [24]
RP   REVIEW ON ROLE IN KIT SIGNALING AND KIT DEGRADATION.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [25]
RP   PHOSPHORYLATION AT TYR-700.
RX   PubMed=15556646; DOI=10.1016/j.febslet.2004.10.054;
RA   Grossmann A.H., Kolibaba K.S., Willis S.G., Corbin A.S., Langdon W.S.,
RA   Deininger M.W., Druker B.J.;
RT   "Catalytic domains of tyrosine kinases determine the phosphorylation
RT   sites within c-Cbl.";
RL   FEBS Lett. 577:555-562(2004).
RN   [26]
RP   FUNCTION, PHOSPHORYLATION AT TYR-731, AND MUTAGENESIS OF TYR-731.
RX   PubMed=14739300; DOI=10.1074/jbc.M311032200;
RA   Miyazaki T., Sanjay A., Neff L., Tanaka S., Horne W.C., Baron R.;
RT   "Src kinase activity is essential for osteoclast function.";
RL   J. Biol. Chem. 279:17660-17666(2004).
RN   [27]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH FGFR2; LYN AND FYN.
RX   PubMed=15190072; DOI=10.1074/jbc.M402469200;
RA   Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J.;
RT   "Cbl-mediated degradation of Lyn and Fyn induced by constitutive
RT   fibroblast growth factor receptor-2 activation supports osteoblast
RT   differentiation.";
RL   J. Biol. Chem. 279:36259-36267(2004).
RN   [28]
RP   INTERACTION WITH ALK, AND PHOSPHORYLATION BY ALK.
RX   PubMed=15226403; DOI=10.1242/jcs.01183;
RA   Motegi A., Fujimoto J., Kotani M., Sakuraba H., Yamamoto T.;
RT   "ALK receptor tyrosine kinase promotes cell growth and neurite
RT   outgrowth.";
RL   J. Cell Sci. 117:3319-3329(2004).
RN   [29]
RP   INTERACTION WITH AXL.
RX   PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086;
RA   Valverde P.;
RT   "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and
RT   downregulation.";
RL   Biochem. Biophys. Res. Commun. 333:180-185(2005).
RN   [30]
RP   REVIEW ON ROLE IN KIT SIGNALING AND KIT DEGRADATION.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-900, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [33]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION.
RX   PubMed=17509076; DOI=10.1111/j.1742-4658.2007.05835.x;
RA   Bonaventure J., Horne W.C., Baron R.;
RT   "The localization of FGFR3 mutations causing thanatophoric dysplasia
RT   type I differentially affects phosphorylation, processing and
RT   ubiquitylation of the receptor.";
RL   FEBS J. 274:3078-3093(2007).
RN   [34]
RP   INTERACTION WITH PDGFRB.
RX   PubMed=17620338; DOI=10.1074/jbc.M701797200;
RA   Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P.,
RA   Druker B.J., Naramura M., Band V., Band H.;
RT   "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-
RT   derived growth factor receptor beta provides a dual mechanism of
RT   negative regulation.";
RL   J. Biol. Chem. 282:29336-29347(2007).
RN   [35]
RP   INTERACTION WITH LYN.
RX   PubMed=18235045; DOI=10.1182/blood-2007-08-109330;
RA   Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M.,
RA   Donato N.J.;
RT   "Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl
RT   protein stability in imatinib-resistant chronic myelogenous leukemia
RT   cells.";
RL   Blood 111:3821-3829(2008).
RN   [36]
RP   FUNCTION, INTERACTION WITH FGFR2, AND SUBCELLULAR LOCATION.
RX   PubMed=18374639; DOI=10.1016/j.bone.2008.02.009;
RA   Dufour C., Guenou H., Kaabeche K., Bouvard D., Sanjay A., Marie P.J.;
RT   "FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt
RT   signaling and osteoblast survival.";
RL   Bone 42:1032-1039(2008).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [38]
RP   INTERACTION WITH EPHB1, AND PHOSPHORYLATION.
RX   PubMed=18034775; DOI=10.1111/j.1600-0854.2007.00679.x;
RA   Fasen K., Cerretti D.P., Huynh-Do U.;
RT   "Ligand binding induces Cbl-dependent EphB1 receptor degradation
RT   through the lysosomal pathway.";
RL   Traffic 9:251-266(2008).
RN   [39]
RP   INTERACTION WITH TEK/TIE2, AND FUNCTION.
RX   PubMed=19689429; DOI=10.1042/BJ20091010;
RA   Wehrle C., Van Slyke P., Dumont D.J.;
RT   "Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required
RT   for internalization and degradation.";
RL   Biochem. J. 423:375-380(2009).
RN   [40]
RP   INTERACTION WITH EGFR.
RX   PubMed=19836242; DOI=10.1016/j.cub.2009.09.048;
RA   Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F.,
RA   Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y.;
RT   "An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase
RT   controlling EGFR endocytosis.";
RL   Curr. Biol. 19:1788-1798(2009).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [42]
RP   INTERACTION WITH PDGFRB, AND PHOSPHORYLATION.
RX   PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004;
RA   Wardega P., Heldin C.H., Lennartsson J.;
RT   "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects
RT   cell proliferation but not migration.";
RL   Cell. Signal. 22:1363-1368(2010).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [45]
RP   FUNCTION, AND INTERACTION WITH FGFR2.
RX   PubMed=21596750; DOI=10.1074/jbc.M110.197525;
RA   Severe N., Miraoui H., Marie P.J.;
RT   "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic
RT   differentiation in human mesenchymal stromal cells in part by
RT   decreased Cbl-mediated platelet-derived growth factor receptor alpha
RT   and fibroblast growth factor receptor 2 ubiquitination.";
RL   J. Biol. Chem. 286:24443-24450(2011).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439; SER-483 AND
RP   SER-669, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [47]
RP   CHARACTERIZATION OF VARIANTS NSLL GLU-382; TYR-390 AND GLN-420.
RX   PubMed=25178484; DOI=10.1002/humu.22682;
RA   Brand K., Kentsch H., Glashoff C., Rosenberger G.;
RT   "RASopathy-associated CBL germline mutations cause aberrant
RT   ubiquitylation and trafficking of EGFR.";
RL   Hum. Mutat. 35:1372-1381(2014).
RN   [48]
RP   REVIEW ON FUNCTION IN FGF SIGNALING, AND UBIQUITINATION OF FGFR1.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 47-350 IN COMPLEX WITH ZAP70
RP   PEPTIDE AND CALCIUM IONS, CALCIUM-BINDING SITE, AND MUTAGENESIS OF
RP   SER-80; PRO-82; ASP-229; GLU-240; ARG-294 AND GLY-306.
RX   PubMed=10078535; DOI=10.1038/18050;
RA   Meng W., Sawasdikosol S., Burakoff S.J., Eck M.J.;
RT   "Structure of the amino-terminal domain of Cbl complexed to its
RT   binding site on ZAP-70 kinase.";
RL   Nature 398:84-90(1999).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 47-434 IN COMPLEX WITH ZAP70
RP   AND UBE2L3.
RX   PubMed=10966114; DOI=10.1016/S0092-8674(00)00057-X;
RA   Zheng N., Wang P., Jeffrey P.D., Pavletich N.P.;
RT   "Structure of a c-Cbl-UbcH7 complex: RING domain function in
RT   ubiquitin-protein ligases.";
RL   Cell 102:533-539(2000).
RN   [51]
RP   VARIANTS NSLL PRO-367; GLU-382; TYR-390 AND GLN-420, AND
RP   CHARACTERIZATION OF VARIANTS NSLL TYR-390 AND GLN-420.
RX   PubMed=20619386; DOI=10.1016/j.ajhg.2010.06.015;
RA   Martinelli S., De Luca A., Stellacci E., Rossi C., Checquolo S.,
RA   Lepri F., Caputo V., Silvano M., Buscherini F., Consoli F.,
RA   Ferrara G., Digilio M.C., Cavaliere M.L., van Hagen J.M., Zampino G.,
RA   van der Burgt I., Ferrero G.B., Mazzanti L., Screpanti I.,
RA   Yntema H.G., Nillesen W.M., Savarirayan R., Zenker M.,
RA   Dallapiccola B., Gelb B.D., Tartaglia M.;
RT   "Heterozygous germline mutations in the CBL tumor-suppressor gene
RT   cause a Noonan syndrome-like phenotype.";
RL   Am. J. Hum. Genet. 87:250-257(2010).
RN   [52]
RP   VARIANTS ARG-287; SER-LYS-365 INS; HIS-371 AND LEU-499,
RP   CHARACTERIZATION OF VARIANTS SER-LYS-365 INS AND HIS-371, AND
RP   PHOSPHORYLATION AT TYR-674; TYR-700 AND TYR-774.
RX   PubMed=20622007; DOI=10.1074/jbc.M110.106161;
RA   Fernandes M.S., Reddy M.M., Croteau N.J., Walz C., Weisbach H.,
RA   Podar K., Band H., Carroll M., Reiter A., Larson R.A., Salgia R.,
RA   Griffin J.D., Sattler M.;
RT   "Novel oncogenic mutations of CBL in human acute myeloid leukemia that
RT   activate growth and survival pathways depend on increased
RT   metabolism.";
RL   J. Biol. Chem. 285:32596-32605(2010).
CC   -!- FUNCTION: Adapter protein that functions as a negative regulator
CC       of many signaling pathways that are triggered by activation of
CC       cell surface receptors. Acts as an E3 ubiquitin-protein ligase,
CC       which accepts ubiquitin from specific E2 ubiquitin-conjugating
CC       enzymes, and then transfers it to substrates promoting their
CC       degradation by the proteasome. Recognizes activated receptor
CC       tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA,
CC       PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling.
CC       Recognizes membrane-bound HCK, SRC and other kinases of the SRC
CC       family and mediates their ubiquitination and degradation.
CC       Participates in signal transduction in hematopoietic cells. Plays
CC       an important role in the regulation of osteoblast differentiation
CC       and apoptosis. Essential for osteoclastic bone resorption. The
CC       'Tyr-731' phosphorylated form induces the activation and
CC       recruitment of phosphatidylinositol 3-kinase to the cell membrane
CC       in a signaling pathway that is critical for osteoclast function.
CC       May be functionally coupled with the E2 ubiquitin-protein ligase
CC       UB2D3. {ECO:0000269|PubMed:10514377, ECO:0000269|PubMed:11896602,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:14739300,
CC       ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:17509076,
CC       ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19689429,
CC       ECO:0000269|PubMed:21596750}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:10514377,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:17509076}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts (phosphorylated at Tyr-731) with PIK3R1.
CC       Associates with NCK via its SH3 domain. The phosphorylated C-
CC       terminus interacts with CD2AP via its second SH3 domain. Binds to
CC       UBE2L3. Interacts with adapters SLA, SLA2 and with the
CC       phosphorylated C-terminus of SH2B2. Interacts with EGFR, SYK and
CC       ZAP70 via the highly conserved Cbl-N region. Also interacts with
CC       SORBS1 and INPPL1/SHIP2. Interacts with phosphorylated LAT2. May
CC       interact with CBLB (By similarity). Interacts with ALK, AXL, BLK,
CC       FGR and FGFR2. Interacts with CSF1R, EPHB1, FLT1, KDR, PDGFRA and
CC       PDGFRB; regulates receptor degradation through ubiquitination.
CC       Interacts with HCK and LYN. Interacts with TEK/TIE2 (tyrosine
CC       phosphorylated). Interacts with SH3KBP1 and this interaction is
CC       inhibited in the presence of SHKBP1 (By similarity).
CC       {ECO:0000250|UniProtKB:P22682, ECO:0000269|PubMed:10078535,
CC       ECO:0000269|PubMed:10092522, ECO:0000269|PubMed:10374881,
CC       ECO:0000269|PubMed:10449770, ECO:0000269|PubMed:10966114,
CC       ECO:0000269|PubMed:11067845, ECO:0000269|PubMed:11696592,
CC       ECO:0000269|PubMed:11850825, ECO:0000269|PubMed:11896602,
CC       ECO:0000269|PubMed:11997497, ECO:0000269|PubMed:12435267,
CC       ECO:0000269|PubMed:12486104, ECO:0000269|PubMed:12504111,
CC       ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15226403,
CC       ECO:0000269|PubMed:15958209, ECO:0000269|PubMed:17620338,
CC       ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:18235045,
CC       ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19689429,
CC       ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:20494825,
CC       ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:7657591,
CC       ECO:0000269|PubMed:8083187, ECO:0000269|PubMed:9407100,
CC       ECO:0000269|PubMed:9989826}.
CC   -!- INTERACTION:
CC       Q8IZP0-2:ABI1; NbExp=3; IntAct=EBI-518228, EBI-7358775;
CC       Q14155:ARHGEF7; NbExp=9; IntAct=EBI-518228, EBI-717515;
CC       Q9Y5K6:CD2AP; NbExp=4; IntAct=EBI-518228, EBI-298152;
CC       P46108:CRK; NbExp=8; IntAct=EBI-518228, EBI-886;
CC       P46109:CRKL; NbExp=3; IntAct=EBI-518228, EBI-910;
CC       P00533:EGFR; NbExp=21; IntAct=EBI-518228, EBI-297353;
CC       P55085:F2RL1; NbExp=3; IntAct=EBI-518228, EBI-4303189;
CC       P17948:FLT1; NbExp=2; IntAct=EBI-518228, EBI-1026718;
CC       P39688:Fyn (xeno); NbExp=3; IntAct=EBI-518228, EBI-524514;
CC       P62993:GRB2; NbExp=10; IntAct=EBI-518228, EBI-401755;
CC       P08631-2:HCK; NbExp=2; IntAct=EBI-518228, EBI-9834454;
CC       Q15811:ITSN1; NbExp=12; IntAct=EBI-518228, EBI-602041;
CC       P45983:MAPK8; NbExp=2; IntAct=EBI-518228, EBI-286483;
CC       P08581:MET; NbExp=15; IntAct=EBI-518228, EBI-1039152;
CC       P04629:NTRK1; NbExp=2; IntAct=EBI-518228, EBI-1028226;
CC       P27986:PIK3R1; NbExp=5; IntAct=EBI-518228, EBI-79464;
CC       O00459:PIK3R2; NbExp=4; IntAct=EBI-518228, EBI-346930;
CC       Q92569:PIK3R3; NbExp=4; IntAct=EBI-518228, EBI-79893;
CC       P08487:PLCG1 (xeno); NbExp=3; IntAct=EBI-518228, EBI-8013886;
CC       O14492:SH2B2; NbExp=7; IntAct=EBI-518228, EBI-7507432;
CC       Q96B97:SH3KBP1; NbExp=18; IntAct=EBI-518228, EBI-346595;
CC       O43597:SPRY2; NbExp=17; IntAct=EBI-518228, EBI-742487;
CC       Q9C004:SPRY4; NbExp=9; IntAct=EBI-518228, EBI-354861;
CC       P12931:SRC; NbExp=8; IntAct=EBI-518228, EBI-621482;
CC       P43405:SYK; NbExp=2; IntAct=EBI-518228, EBI-78302;
CC       P31946:YWHAB; NbExp=3; IntAct=EBI-518228, EBI-359815;
CC       P27348:YWHAQ; NbExp=6; IntAct=EBI-518228, EBI-359854;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Note=Colocalizes
CC       with FGFR2 in lipid rafts at the cell membrane.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme.
CC   -!- DOMAIN: The N-terminus is composed of the phosphotyrosine binding
CC       (PTB) domain, a short linker region and the RING-type zinc finger.
CC       The PTB domain, which is also called TKB (tyrosine kinase binding)
CC       domain, is composed of three different subdomains: a four-helix
CC       bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
CC   -!- PTM: Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN
CC       and ZAP70 (By similarity). Phosphorylated on tyrosine residues in
CC       response to FLT1 and KIT signaling. Phosphorylated on tyrosine
CC       residues by INSR and FGR. Phosphorylated on several tyrosine
CC       residues by constitutively activated FGFR3. Not phosphorylated at
CC       Tyr-731 by FGFR3. Phosphorylated on tyrosine residues by activated
CC       CSF1R, PDGFRA and PDGFRB. Phosphorylated on tyrosine residues by
CC       HCK. {ECO:0000250, ECO:0000269|PubMed:10092522,
CC       ECO:0000269|PubMed:11850825, ECO:0000269|PubMed:11997497,
CC       ECO:0000269|PubMed:12435267, ECO:0000269|PubMed:14739300,
CC       ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15226403,
CC       ECO:0000269|PubMed:15556646, ECO:0000269|PubMed:17509076,
CC       ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:20494825,
CC       ECO:0000269|PubMed:20622007, ECO:0000269|PubMed:7657591,
CC       ECO:0000269|PubMed:9535867}.
CC   -!- PTM: Ubiquitinated, leading to its degradation via the proteasome.
CC       {ECO:0000269|PubMed:11896602, ECO:0000269|PubMed:20094046}.
CC   -!- DISEASE: Noonan syndrome-like disorder with or without juvenile
CC       myelomonocytic leukemia (NSLL) [MIM:613563]: A syndrome
CC       characterized by a phenotype reminiscent of Noonan syndrome.
CC       Clinical features are highly variable, including facial
CC       dysmorphism, short neck, developmental delay, hyperextensible
CC       joints and thorax abnormalities with widely spaced nipples. The
CC       facial features consist of triangular face with hypertelorism,
CC       large low-set ears, ptosis, and flat nasal bridge. Some patients
CC       manifest cardiac defects. Some have an increased risk for certain
CC       malignancies, particularly juvenile myelomonocytic leukemia.
CC       {ECO:0000269|PubMed:20619386, ECO:0000269|PubMed:25178484}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: This protein has one functional calcium-binding
CC       site.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBLID171.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57110; CAA40393.1; -; mRNA.
DR   EMBL; AP002956; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC132733; AAI32734.1; -; mRNA.
DR   EMBL; BC136463; AAI36464.1; -; mRNA.
DR   CCDS; CCDS8418.1; -.
DR   PIR; A43817; A43817.
DR   RefSeq; NP_005179.2; NM_005188.3.
DR   UniGene; Hs.504096; -.
DR   PDB; 1B47; X-ray; 2.20 A; A/B/C=47-350.
DR   PDB; 1FBV; X-ray; 2.90 A; A=47-434.
DR   PDB; 1YVH; X-ray; 2.05 A; A=25-351.
DR   PDB; 2CBL; X-ray; 2.10 A; A=47-351.
DR   PDB; 2JUJ; NMR; -; A=851-906.
DR   PDB; 2K4D; NMR; -; A=358-437.
DR   PDB; 2OO9; X-ray; 2.10 A; A/B/C=856-895.
DR   PDB; 2Y1M; X-ray; 2.67 A; A/B/C/D/E/F=47-435.
DR   PDB; 2Y1N; X-ray; 2.00 A; A/C=47-435.
DR   PDB; 3BUM; X-ray; 2.00 A; B=25-351.
DR   PDB; 3BUN; X-ray; 2.00 A; B=25-351.
DR   PDB; 3BUO; X-ray; 2.60 A; B/D=25-351.
DR   PDB; 3BUW; X-ray; 1.45 A; B/D=25-351.
DR   PDB; 3BUX; X-ray; 1.35 A; B/D=25-351.
DR   PDB; 3OB1; X-ray; 2.20 A; B=25-351.
DR   PDB; 3OB2; X-ray; 2.10 A; B=25-351.
DR   PDB; 3PLF; X-ray; 1.92 A; B/D=25-351.
DR   PDB; 4A49; X-ray; 2.21 A; A=354-435.
DR   PDB; 4A4B; X-ray; 2.79 A; A=47-435.
DR   PDB; 4A4C; X-ray; 2.70 A; A=47-435.
DR   PDB; 4GPL; X-ray; 3.00 A; B=47-351.
DR   PDB; 5HKW; X-ray; 2.25 A; A/B/C=47-351.
DR   PDB; 5HKX; X-ray; 1.85 A; A=47-435.
DR   PDB; 5HKY; X-ray; 1.80 A; A=47-351.
DR   PDB; 5HKZ; X-ray; 1.80 A; A=47-351.
DR   PDB; 5HL0; X-ray; 2.20 A; A=47-351.
DR   PDB; 5J3X; X-ray; 2.82 A; A/B/C/D/E/F=47-435.
DR   PDBsum; 1B47; -.
DR   PDBsum; 1FBV; -.
DR   PDBsum; 1YVH; -.
DR   PDBsum; 2CBL; -.
DR   PDBsum; 2JUJ; -.
DR   PDBsum; 2K4D; -.
DR   PDBsum; 2OO9; -.
DR   PDBsum; 2Y1M; -.
DR   PDBsum; 2Y1N; -.
DR   PDBsum; 3BUM; -.
DR   PDBsum; 3BUN; -.
DR   PDBsum; 3BUO; -.
DR   PDBsum; 3BUW; -.
DR   PDBsum; 3BUX; -.
DR   PDBsum; 3OB1; -.
DR   PDBsum; 3OB2; -.
DR   PDBsum; 3PLF; -.
DR   PDBsum; 4A49; -.
DR   PDBsum; 4A4B; -.
DR   PDBsum; 4A4C; -.
DR   PDBsum; 4GPL; -.
DR   PDBsum; 5HKW; -.
DR   PDBsum; 5HKX; -.
DR   PDBsum; 5HKY; -.
DR   PDBsum; 5HKZ; -.
DR   PDBsum; 5HL0; -.
DR   PDBsum; 5J3X; -.
DR   ProteinModelPortal; P22681; -.
DR   SMR; P22681; -.
DR   BioGrid; 107315; 246.
DR   DIP; DIP-189N; -.
DR   IntAct; P22681; 86.
DR   MINT; MINT-109040; -.
DR   STRING; 9606.ENSP00000264033; -.
DR   iPTMnet; P22681; -.
DR   PhosphoSitePlus; P22681; -.
DR   BioMuta; CBL; -.
DR   DMDM; 251757253; -.
DR   EPD; P22681; -.
DR   MaxQB; P22681; -.
DR   PaxDb; P22681; -.
DR   PeptideAtlas; P22681; -.
DR   PRIDE; P22681; -.
DR   Ensembl; ENST00000264033; ENSP00000264033; ENSG00000110395.
DR   GeneID; 867; -.
DR   KEGG; hsa:867; -.
DR   UCSC; uc001pwe.5; human.
DR   CTD; 867; -.
DR   DisGeNET; 867; -.
DR   GeneCards; CBL; -.
DR   HGNC; HGNC:1541; CBL.
DR   HPA; CAB004350; -.
DR   HPA; HPA027956; -.
DR   MalaCards; CBL; -.
DR   MIM; 165360; gene.
DR   MIM; 613563; phenotype.
DR   neXtProt; NX_P22681; -.
DR   OpenTargets; ENSG00000110395; -.
DR   Orphanet; 86834; Juvenile myelomonocytic leukemia.
DR   Orphanet; 363972; Noonan syndrome-like disorder with juvenile myelomonocytic leukemia.
DR   PharmGKB; PA26115; -.
DR   eggNOG; KOG1785; Eukaryota.
DR   eggNOG; ENOG410YDNH; LUCA.
DR   GeneTree; ENSGT00390000011617; -.
DR   HOGENOM; HOG000294176; -.
DR   HOVERGEN; HBG005255; -.
DR   InParanoid; P22681; -.
DR   KO; K04707; -.
DR   OMA; EQCESEE; -.
DR   OrthoDB; EOG091G0GPE; -.
DR   PhylomeDB; P22681; -.
DR   TreeFam; TF314210; -.
DR   BRENDA; 2.3.2.B10; 2681.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-182971; EGFR downregulation.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-6807004; Negative regulation of MET activity.
DR   Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8875360; InlB-mediated entry of Listeria monocytogenes into host cell.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P22681; -.
DR   SIGNOR; P22681; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; CBL; human.
DR   EvolutionaryTrace; P22681; -.
DR   GeneWiki; CBL_(gene); -.
DR   GenomeRNAi; 867; -.
DR   PMAP-CutDB; P22681; -.
DR   PRO; PR:P22681; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000110395; -.
DR   CleanEx; HS_CBL; -.
DR   ExpressionAtlas; P22681; baseline and differential.
DR   Genevisible; P22681; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016600; C:flotillin complex; IEA:Ensembl.
DR   GO; GO:0005925; C:focal adhesion; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0045121; C:membrane raft; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HGNC.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:UniProtKB.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:0036312; F:phosphatidylinositol 3-kinase regulatory subunit binding; IEA:Ensembl.
DR   GO; GO:0001784; F:phosphotyrosine binding; IEA:InterPro.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:BHF-UCL.
DR   GO; GO:0004871; F:signal transducer activity; IEA:InterPro.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; TAS:ProtInc.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; TAS:HGNC.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:HGNC.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEA:Ensembl.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0090650; P:cellular response to oxygen-glucose deprivation; IEA:Ensembl.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0035635; P:entry of bacterium into host cell; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:HGNC.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0043303; P:mast cell degranulation; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007175; P:negative regulation of epidermal growth factor-activated receptor activity; IBA:GO_Central.
DR   GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0070997; P:neuron death; IEA:Ensembl.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:BHF-UCL.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; IMP:UniProtKB.
DR   GO; GO:0006513; P:protein monoubiquitination; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Ensembl.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:HGNC.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   CDD; cd00162; RING; 1.
DR   CDD; cd09920; SH2_Cbl-b_TKB; 1.
DR   Gene3D; 1.20.930.20; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR024162; Adaptor_Cbl.
DR   InterPro; IPR014741; Adaptor_Cbl_EF_hand-like.
DR   InterPro; IPR003153; Adaptor_Cbl_N_hlx.
DR   InterPro; IPR014742; Adaptor_Cbl_SH2-like.
DR   InterPro; IPR024159; Cbl_PTB.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR009060; UBA-like.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR23007; PTHR23007; 1.
DR   Pfam; PF02262; Cbl_N; 1.
DR   Pfam; PF02761; Cbl_N2; 1.
DR   Pfam; PF02762; Cbl_N3; 1.
DR   Pfam; PF00627; UBA; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF46934; SSF46934; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF47668; SSF47668; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS51506; CBL_PTB; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell membrane; Complete proteome; Cytoplasm;
KW   Disease mutation; Membrane; Metal-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; Repeat; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    906       E3 ubiquitin-protein ligase CBL.
FT                                /FTId=PRO_0000055858.
FT   DOMAIN       47    351       Cbl-PTB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00839}.
FT   DOMAIN      856    895       UBA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00212}.
FT   CA_BIND     227    240
FT   ZN_FING     381    420       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION        1    357       Sufficient for interaction with EPHB1.
FT                                {ECO:0000269|PubMed:18034775}.
FT   REGION       47    175       4H.
FT   REGION      176    248       EF-hand-like.
FT   REGION      249    351       SH2-like.
FT   REGION      352    380       Linker.
FT   REGION      648    906       Interaction with CD2AP.
FT                                {ECO:0000269|PubMed:11067845}.
FT   COMPBIAS    357    476       Asp/Glu-rich (acidic).
FT   COMPBIAS    477    688       Pro-rich.
FT   COMPBIAS    689    834       Asp/Glu-rich (acidic).
FT   BINDING     294    294       Phosphotyrosine. {ECO:0000250}.
FT   MOD_RES     371    371       Phosphotyrosine; by INSR.
FT                                {ECO:0000269|PubMed:11997497}.
FT   MOD_RES     439    439       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     452    452       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     483    483       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     619    619       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P22682}.
FT   MOD_RES     642    642       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P22682}.
FT   MOD_RES     668    668       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P22682}.
FT   MOD_RES     669    669       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     674    674       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:20622007}.
FT   MOD_RES     700    700       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:11997497,
FT                                ECO:0000269|PubMed:15556646,
FT                                ECO:0000269|PubMed:20622007}.
FT   MOD_RES     731    731       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:14739300}.
FT   MOD_RES     774    774       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:11997497,
FT                                ECO:0000269|PubMed:20622007}.
FT   MOD_RES     900    900       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243}.
FT   VARIANT     287    287       K -> R (found in patients with acute
FT                                myeloid leukemia; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20622007}.
FT                                /FTId=VAR_071040.
FT   VARIANT     365    365       Q -> QSK (found in patients with acute
FT                                myeloid leukemia; unknown pathological
FT                                significance; loss of the ability to
FT                                negatively regulate signaling pathways;
FT                                promotes cell cycle progression;
FT                                decreases apoptosis).
FT                                /FTId=VAR_071041.
FT   VARIANT     367    367       Q -> P (in NSLL; dbSNP:rs267606704).
FT                                {ECO:0000269|PubMed:20619386}.
FT                                /FTId=VAR_064332.
FT   VARIANT     371    371       Y -> H (found in patients with acute
FT                                myeloid leukemia; unknown pathological
FT                                significance; loss of the ability to
FT                                negatively regulate signaling pathways;
FT                                promotes cell cycle progression;
FT                                decreases apoptosis; dbSNP:rs267606706).
FT                                {ECO:0000269|PubMed:20622007}.
FT                                /FTId=VAR_071042.
FT   VARIANT     382    382       K -> E (in NSLL; dominant-negative;
FT                                impairs CBL-mediated ubiquitination,
FT                                internalization and degradation of the
FT                                EGF receptor/EGFR; decreases the ability
FT                                to negatively regulate EGFR signaling;
FT                                dbSNP:rs267606705).
FT                                {ECO:0000269|PubMed:25178484}.
FT                                /FTId=VAR_064333.
FT   VARIANT     390    390       D -> Y (in NSLL; dominant-negative;
FT                                impairs CBL-mediated ubiquitination,
FT                                internalization and degradation of the
FT                                EGF receptor/EGFR; decreases the ability
FT                                to negatively regulate EGFR signaling;
FT                                dbSNP:rs267606707).
FT                                {ECO:0000269|PubMed:20619386,
FT                                ECO:0000269|PubMed:25178484}.
FT                                /FTId=VAR_064334.
FT   VARIANT     420    420       R -> Q (in NSLL; dominant-negative;
FT                                impairs CBL-mediated ubiquitination,
FT                                internalization and degradation of the
FT                                EGF receptor/EGFR; decreases the ability
FT                                to negatively regulate EGFR signaling;
FT                                dbSNP:rs267606708).
FT                                {ECO:0000269|PubMed:20619386,
FT                                ECO:0000269|PubMed:25178484}.
FT                                /FTId=VAR_064335.
FT   VARIANT     499    499       R -> L (found in patients with acute
FT                                myeloid leukemia; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20622007}.
FT                                /FTId=VAR_071043.
FT   VARIANT     620    620       L -> F (in dbSNP:rs2227988).
FT                                /FTId=VAR_057211.
FT   VARIANT     782    782       P -> L (in dbSNP:rs2229073).
FT                                /FTId=VAR_057212.
FT   VARIANT     904    904       V -> I (in dbSNP:rs17122769).
FT                                /FTId=VAR_057213.
FT   MUTAGEN      80     80       S->D: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN      82     82       P->A: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN     229    229       D->Q: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN     240    240       E->S: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN     294    294       R->K: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN     306    306       G->E: Abolishes interaction with ZAP70
FT                                and EPHB1, but does not affect
FT                                interaction with SLA.
FT                                {ECO:0000269|PubMed:10078535,
FT                                ECO:0000269|PubMed:10449770}.
FT   MUTAGEN     371    371       Y->F: Strongly reduces tyrosine
FT                                phosphorylation by INSR; when associated
FT                                with F-700 and F-774.
FT                                {ECO:0000269|PubMed:11997497}.
FT   MUTAGEN     381    381       C->A: Loss of ubiquitin ligase activity.
FT                                {ECO:0000269|PubMed:11896602}.
FT   MUTAGEN     700    700       Y->F: Strongly reduces tyrosine
FT                                phosphorylation by INSR; when associated
FT                                with F-371 and F-774.
FT                                {ECO:0000269|PubMed:11997497}.
FT   MUTAGEN     731    731       Y->F: No effect on tyrosine
FT                                phosphorylation by INSR. Loss of
FT                                phosphorylation by SRC. Inhibition of
FT                                bone resorption. Abolishes interaction
FT                                with PIK3R1.
FT                                {ECO:0000269|PubMed:11997497,
FT                                ECO:0000269|PubMed:14739300}.
FT   MUTAGEN     774    774       Y->F: Strongly reduces tyrosine
FT                                phosphorylation by INSR; when associated
FT                                with F-371 and F-700.
FT                                {ECO:0000269|PubMed:11997497}.
FT   CONFLICT     15     15       S -> T (in Ref. 1; CAA40393).
FT                                {ECO:0000305}.
FT   HELIX        53     70       {ECO:0000244|PDB:3BUX}.
FT   HELIX        73     75       {ECO:0000244|PDB:3BUX}.
FT   STRAND       80     82       {ECO:0000244|PDB:5HKY}.
FT   HELIX        84    101       {ECO:0000244|PDB:3BUX}.
FT   TURN        102    104       {ECO:0000244|PDB:5HKY}.
FT   HELIX       106    111       {ECO:0000244|PDB:3BUX}.
FT   HELIX       113    136       {ECO:0000244|PDB:3BUX}.
FT   HELIX       137    141       {ECO:0000244|PDB:3BUX}.
FT   HELIX       146    168       {ECO:0000244|PDB:3BUX}.
FT   HELIX       170    172       {ECO:0000244|PDB:3BUX}.
FT   HELIX       176    178       {ECO:0000244|PDB:3BUX}.
FT   HELIX       184    194       {ECO:0000244|PDB:3BUX}.
FT   STRAND      198    201       {ECO:0000244|PDB:3BUX}.
FT   HELIX       202    212       {ECO:0000244|PDB:3BUX}.
FT   HELIX       218    228       {ECO:0000244|PDB:3BUX}.
FT   STRAND      233    237       {ECO:0000244|PDB:3BUX}.
FT   HELIX       238    247       {ECO:0000244|PDB:3BUX}.
FT   HELIX       251    253       {ECO:0000244|PDB:3BUX}.
FT   HELIX       254    261       {ECO:0000244|PDB:3BUX}.
FT   TURN        262    264       {ECO:0000244|PDB:2Y1M}.
FT   STRAND      268    271       {ECO:0000244|PDB:5HKX}.
FT   HELIX       274    281       {ECO:0000244|PDB:3BUX}.
FT   HELIX       282    284       {ECO:0000244|PDB:3BUX}.
FT   STRAND      290    295       {ECO:0000244|PDB:3BUX}.
FT   STRAND      297    299       {ECO:0000244|PDB:3BUX}.
FT   STRAND      302    308       {ECO:0000244|PDB:3BUX}.
FT   TURN        310    312       {ECO:0000244|PDB:3BUO}.
FT   STRAND      314    317       {ECO:0000244|PDB:3BUX}.
FT   STRAND      320    322       {ECO:0000244|PDB:3BUW}.
FT   HELIX       324    333       {ECO:0000244|PDB:3BUX}.
FT   HELIX       350    352       {ECO:0000244|PDB:5HKX}.
FT   STRAND      354    356       {ECO:0000244|PDB:1FBV}.
FT   STRAND      360    362       {ECO:0000244|PDB:4A49}.
FT   HELIX       365    378       {ECO:0000244|PDB:5HKX}.
FT   TURN        382    384       {ECO:0000244|PDB:5HKX}.
FT   STRAND      385    388       {ECO:0000244|PDB:5HKX}.
FT   STRAND      391    394       {ECO:0000244|PDB:5HKX}.
FT   STRAND      398    400       {ECO:0000244|PDB:2K4D}.
FT   HELIX       402    410       {ECO:0000244|PDB:5HKX}.
FT   TURN        417    419       {ECO:0000244|PDB:5HKX}.
FT   STRAND      425    428       {ECO:0000244|PDB:5HKX}.
FT   STRAND      430    432       {ECO:0000244|PDB:4A49}.
FT   HELIX       856    866       {ECO:0000244|PDB:2OO9}.
FT   HELIX       871    880       {ECO:0000244|PDB:2OO9}.
FT   TURN        881    883       {ECO:0000244|PDB:2OO9}.
FT   HELIX       885    895       {ECO:0000244|PDB:2OO9}.
SQ   SEQUENCE   906 AA;  99633 MW;  1AA6BF67377322CA CRC64;
     MAGNVKKSSG AGGGSGSGGS GSGGLIGLMK DAFQPHHHHH HHLSPHPPGT VDKKMVEKCW
     KLMDKVVRLC QNPKLALKNS PPYILDLLPD TYQHLRTILS RYEGKMETLG ENEYFRVFME
     NLMKKTKQTI SLFKEGKERM YEENSQPRRN LTKLSLIFSH MLAELKGIFP SGLFQGDTFR
     ITKADAAEFW RKAFGEKTIV PWKSFRQALH EVHPISSGLE AMALKSTIDL TCNDYISVFE
     FDIFTRLFQP WSSLLRNWNS LAVTHPGYMA FLTYDEVKAR LQKFIHKPGS YIFRLSCTRL
     GQWAIGYVTA DGNILQTIPH NKPLFQALID GFREGFYLFP DGRNQNPDLT GLCEPTPQDH
     IKVTQEQYEL YCEMGSTFQL CKICAENDKD VKIEPCGHLM CTSCLTSWQE SEGQGCPFCR
     CEIKGTEPIV VDPFDPRGSG SLLRQGAEGA PSPNYDDDDD ERADDTLFMM KELAGAKVER
     PPSPFSMAPQ ASLPPVPPRL DLLPQRVCVP SSASALGTAS KAASGSLHKD KPLPVPPTLR
     DLPPPPPPDR PYSVGAESRP QRRPLPCTPG DCPSRDKLPP VPSSRLGDSW LPRPIPKVPV
     SAPSSSDPWT GRELTNRHSL PFSLPSQMEP RPDVPRLGST FSLDTSMSMN SSPLVGPECD
     HPKIKPSSSA NAIYSLAARP LPVPKLPPGE QCEGEEDTEY MTPSSRPLRP LDTSQSSRAC
     DCDQQIDSCT YEAMYNIQSQ APSITESSTF GEGNLAAAHA NTGPEESENE DDGYDVPKPP
     VPAVLARRTL SDISNASSSF GWLSLDGDPT TNVTEGSQVP ERPPKPFPRR INSERKAGSC
     QQGSGPAASA ATASPQLSSE IENLMSQGYS YQDIQKALVI AQNNIEMAKN ILREFVSISS
     PAHVAT
//
